The expression of microRNA-331-3p and microRNA-23b3 in Egyptian patients with early-stage hepatocellular carcinoma in hepatitis C-related liver cirrhosis

Aboelwafa, Reham A.; Ellakany, Walid Ismail; Gamaleldin, Marwa; Saad, Marwa A.

doi:10.1186/s43066-021-00122-7

Cited by 3 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High accuracy AUC was found regarding AFP and miRNA-331, while miRNA-23b showed moderate accuracy AUC in our study which is in agreement with Wu et al (26). On the other hand, serum miR-331-3p was significantly increased in HCC compared to patients with benign hepatic tumors and was associated with poor HCC prognosis (27). Moreover, miR-23b-3p showed a significant decrease in the plasma of patients with early HCC compared to cirrhotic patients.…”

Section: Discussion Discussionsupporting

confidence: 91%

Impact of miR-23b and miR-331 Gene Expressions on HCV-Related Hepatocellular Carcinoma in Egyptian Patients

Omran¹,

Sherif²,

Khalil³

et al. 2023

SGO

View full text Add to dashboard Cite

Background: Hepatocellular carcinoma (HCC) is a major type of liver tumor. It represents up to 90% of all liver malignancies. There are currently no reliable tumor markers or imaging technologies that can accurately diagnose early HCC. The use of circulating micro-RNAs (miRNAs or miR) as a potential tool for early detection of HCC has become an emerging area of study. Objectives: This study aimed to evaluate the role of miR-23b and miR-331 as biomarkers in HCC and chronic hepatitis C (CHC) patients. Patients and Methods: This study included 100 subjects, selected from outpatient clinics of Damanhur Oncology Center from 1/1/2020 to 19/12/2021, they were classified into three groups. Group 1 included 40 patients with HCC, group 2 included 40 patients with chronic hepatitis C infection (CHC), and group 3 included 20 healthy control subjects. Complete blood count (CBC), liver function tests, Alfa fetoprotein (AFP) in addition to miR-23b and miR-331 was estimated in the serum of each studied groups. Results: miRNA-23b gene expression level was significantly decreased in the HCC group when compared to the HCV and control groups. On the other hand, miRNA-331 gene expression level showed significantly higher expression level in the HCC group when compared to the HCV and control groups. The miRNA-23b gene expression level showed significantly decreased level associated with increased BCLC stage, increased tumor size, multiplicity. While higher miRNA-331 gene expression level was significantly associated with higher BCLC stage, larger tumor size, multiple lesions. Conclusion: Serum miR-331 and miR-23b are suggested to be predictors for development and complications of HCC.

show abstract

Section: Discussion Discussionsupporting

confidence: 91%

Impact of miR-23b and miR-331 Gene Expressions on HCV-Related Hepatocellular Carcinoma in Egyptian Patients

Omran¹,

Sherif²,

Khalil³

et al. 2023

SGO

View full text Add to dashboard Cite

show abstract

Circulating microRNA-21, microRNA-122, and microRNA-222 as diagnostic biomarkers for hepatitis c virus-related hepatocellular carcinoma

Hetta,

Hamed,

Mekky

et al. 2024

Egypt Liver Journal

View full text Add to dashboard Cite

Background and aim MicroRNAs (miRs) are now a well-known subject in various tumor genesis and are studied as early diagnostic biomarker. Many arrays of miRs were incorporated in the pathogenesis of HCV-related hepatocellular carcinomas (HCV-HCC). In this respect, we aimed to evaluate the diagnostic role of circulating miR-21, miR-122, and miR-222 in Egyptian patients with HCV-HCC. Patient and methods Between June 2018 and April 2019, a cross-sectional comparative study was designed to evaluate the circulating miR-21, miR-122, and miR-222 by quantitative Real-Time PCR. For analytical purposes, patients were categorized into three groups: chronic HCV group (CHC-group, n = 22), HCV-related liver cirrhosis (LC-group, n = 22), and HCV-related hepatocellular carcinoma (HCV-HCC-group, n = 54). Results Serum levels of miR-21 and miR-222 increased with the progressive course from CHC to LC and HCC; p < .001. Serum levels of miR-122 in HCC patients were significantly lower than non-HCC patients (CHC and LC patients, n = 44); p < .001. However, the differences in levels of serum miR-122 between CHC and LC were not statistically significant; P = 0.8. ROC curve analysis showed that the sensitivity and specificity of miR-21 were 61.1% and 95.5%, miR-222 were 71.7% and 93.2%, and miR-122 were 98.2% and 100%. The positive predictive value for miRNA-21, miRNA-122, and miRNA-222 were 13.4%, 93.3%, and 10.5% respectively. The Negative predictive value for miRNA-21, miRNA-122, and miRNA-222 were 94.3%, 97.8%, and 92.7% respectively. Conclusion MiR-21 and miR-222 could be potential markers for advanced liver damage, while miR-122 had the best diagnostic accuracy and could be a promising marker for detection of HCC.

show abstract

Diagnostic accuracy of circulating miRNAs to discriminate hepatocellular carcinoma from liver cirrhosis: a systematic review and meta-analysis

Alemayehu,

Belete,

Walle

et al. 2024

Front. Med.

View full text Add to dashboard Cite

IntroductionHepatocellular carcinoma (HCC) and liver cirrhosis (LC) stand as the primary causes of global mortality. Given their profound impact, the development of highly sensitive and specific circulating diagnostic markers becomes imperative to effectively identify and differentiate between cirrhosis and HCC. Accurate diagnosis is paramount in guiding appropriate therapeutic interventions. Hence, this study aimed to evaluate the potential of microRNAs (miRNAs) in discerning between HCC and LC.MethodsThis study followed the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, with the protocol officially registered on PROSPERO under the reference number CRD42023417494. A thorough search across multiple databases like PubMed, Embase, Scopus, Wiley Online Library, and Science Direct was conducted to identify relevant studies published from January 1, 2018, to August 10, 2023. The included studies underwent methodological quality assessment using the Quality Assessment of Diagnostic Accuracy Studies 2 (QADAS-2) tool. The synthesis of pooled sensitivity, specificity, and other relevant diagnostic parameters employed a random-effects model and was conducted using Stata 14.0. Heterogeneity was assessed using I2 and Cochrane Q, with subsequent subgroup analysis and meta-regression performed to identify potential sources of observed heterogeneity. A sensitivity analysis was performed to assess the resilience of the findings. Furthermore, Deeks’ funnel plot was employed to evaluate publication bias.ResultsIn this meta-analysis, we included fifteen publications, encompassing 787 HCC patients and 784 LC patients. The combined sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR), and area under the curve (AUC) values of miRNAs in differentiating HCC from LC were 0.84 (95% CI: 0.78–0.88), 0.79 (95% CI: 0.73–0.84), 3.9 (95% CI: 3.0–5.2), 0.21 (95% CI: 0.14–0.29), 19.44 (95% CI: 11–34), and 0.88 (95% CI: 0.85–0.91), respectively. The results of the subgroup analysis revealed that upregulated miRNA levels and miRNA assessments specifically for individuals of European descent exhibited superior diagnostic performance.ConclusionThe results of this study suggested that circulating miRNAs, especially those that are upregulated, have the potential to function as robust and promising biomarkers in the differentiation of HCC from LC.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42023475954.

show abstract

The expression of microRNA-331-3p and microRNA-23b3 in Egyptian patients with early-stage hepatocellular carcinoma in hepatitis C-related liver cirrhosis

Cited by 3 publications

References 23 publications

Impact of miR-23b and miR-331 Gene Expressions on HCV-Related Hepatocellular Carcinoma in Egyptian Patients

Impact of miR-23b and miR-331 Gene Expressions on HCV-Related Hepatocellular Carcinoma in Egyptian Patients

Circulating microRNA-21, microRNA-122, and microRNA-222 as diagnostic biomarkers for hepatitis c virus-related hepatocellular carcinoma

Diagnostic accuracy of circulating miRNAs to discriminate hepatocellular carcinoma from liver cirrhosis: a systematic review and meta-analysis

Contact Info

Product

Resources

About